Economics may complicate the next round of generic drug user fee negotiations, should conditions within the industry not improve.
Generic Industry Market Forces May Impact GDUFA III Talks
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.
